Biotechnology company Bracco Imaging announced its expansion into the cell-therapy manufacturing space, establishing a new ...
Bracco’s cell selection and activation microbubble technology is designed to support both positive- and negative-selection strategies.
Technology based on Bracco’s clinically validated microbubble technology enables gentle, scalable cell selection and activation, streamlining workflows for cell therapyBracco’s microbubbles, an ...
Bracco Imaging is expanding into the cell therapy space to explore new applications of its long-established microbubble technology.
On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...
The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...
Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript February 3, 2026 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.04, expectations were $2.01. Operator: Thank you for ...
EU recommends approval of AstraZeneca’s Imfinzi perioperative regimen for patients with early gastric and gastroesophageal cancers ...
Recommendation based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% ...
February 2026 Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers Recommendation based on MATTERHORN Phase III trial ...
Growing cancer-targeting T-cells in a lab is only half the battle. They must be collected intact. A new IIT Bombay study has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results